Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Commitments (Details Narrative)

v3.22.1
Commitments (Details Narrative)
12 Months Ended
Dec. 31, 2021
CAD ($)
Termination benefits expense $ 300,000
ActivitiesRelatedToClinicalTrialManufacturing $ 1,613,142